



## **Crescent Biopharma Appoints David Lubner to Board of Directors**

*Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations*

**Waltham, Mass., April 28, 2025** – [Crescent Biopharma](#), Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.

“David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy,” said Peter Harwin, chairman of Crescent’s Board of Directors. “His contributions to Crescent will be instrumental as we continue to grow, advance our tetravalent PD-1 x VEGF bispecific antibody and ADC programs for multiple solid tumors, and ultimately build a world leading oncology company.”

“With an exciting pipeline, experienced management and support from leading biotechnology investors, Crescent is well-positioned to usher in the next wave of innovation in cancer therapy,” said Mr. Lubner. “I look forward to collaborating with Crescent’s Board and executive team to deliver potentially best-in-class therapeutics for solid tumors that can transform the standard of care for patients.”

David Lubner is a seasoned finance executive with 30 years of experience in the life sciences industry. Mr. Lubner served as executive vice president and chief financial officer (CFO) of Ra Pharmaceuticals, acquired by UCB in 2020. Prior to that, he was CFO of Tetrphase Pharmaceuticals and was previously CFO of PharMetrics until it was acquired by IMS Health. He also held the CFO position at ProScript, where Velcade<sup>®</sup>, a therapy widely used for the treatment of multiple myeloma, was discovered. Mr. Lubner currently serves on the boards of directors of Arcellx, Cargo Therapeutics, Dyne Therapeutics and Vor Biopharma as well as several private companies. He previously served on the board of directors of Nightstar Therapeutics, until it was acquired by Biogen, and Point Biopharma, until its acquisition by Eli Lilly & Company. Mr. Lubner received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Crescent is developing novel precision-engineered molecules to improve outcomes for patients with solid tumors. Crescent’s lead program, CR-001, a tetravalent PD-1 x VEGF bispecific antibody, is on track for an Investigational New Drug (IND) application submission in the fourth quarter of 2025. In October 2024, Crescent [entered into an acquisition agreement](#) with GlycoMimetics, Inc. (Nasdaq: GLYC). Following closing, which is anticipated in the second quarter of 2025, the combined company will operate under the name Crescent Biopharma and advance Crescent’s portfolio.

### **About Crescent Biopharma**

Crescent Biopharma, Inc. is a biotechnology company advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s pipeline of three programs harnesses validated biology to accelerate the path to market for potentially best-in-class therapeutics. Crescent’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and it is also advancing CR-002 and CR-003, antibody drug conjugates with topoisomerase inhibitor payloads for undisclosed targets. For more information, visit [www.crescentbiopharma.com](http://www.crescentbiopharma.com) and follow us on [LinkedIn](#).



**Contact**

Amy Reilly

Chief Communications Officer

[amy.reilly@crescentbiopharma.com](mailto:amy.reilly@crescentbiopharma.com)

617-465-0586